Applications are open for projects into diseases affecting companion animals.
Funding of up to £20,000 for a companion animal research project lasting between one and three years has been made available by BSAVA PetSavers.
The move follows a decision by the BSAVA PetSavers management committee to increase the value of their Clinical Research Project (CRP) grant funding, which is available for projects into diseases affecting companion animals.
The increased funds can be used to cover research expenses and consumables, with up to 30 per cent for research-specific staffing costs. Ultimately, the aim of the funding is to advance understanding of the causes or management of a clinical disorder.
Jeremy Kirk, incoming chair of the PetSavers Grant Awarding Committee, said: "We recognise that increased funding may be needed in order to support meaningful research which will benefit the lives of companion animals. The higher level of funding also comes with increased flexibility to facilitate the projects and encourage a diverse range of applications."
David Killick, current Grant Awarding Committee chair, added: “We believe this additional funding will help PetSavers funded research answer clinically relevant questions more deeply and allow their discoveries to be brought to the clinic for the benefit of our patients more swiftly than before.”
In addition to the increased funding, BSAVA PetSavers has also reopened its grant call for joint-funded research in specialist areas of veterinary science. The organisation offers grants of up to £10,000 for research in veterinary cardiovascular health, feline and/or canine medical conditions, and pain management in companion animals.
Applications for all grants will remain open until 31st January 2023, with a funding decision to be reached in autumn 2023. Projects must be conducted within the UK and must not include work on experimental animals
For more information and to apply, visit the BSAVA PetSavers website.
Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.
